Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.

@article{PinillaIbarz2000VaccinationOP,
  title={Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.},
  author={Javier Pinilla-Ibarz and Kathleen N. S. Cathcart and Tatyana Korontsvit and S Soignet and Monica Bocchia and Janine Caggiano and Laijun Lai and J. Villar Jim{\'e}nez and Jonathan E Kolitz and David A. Scheinberg},
  journal={Blood},
  year={2000},
  volume={95 5},
  pages={1781-7}
}
Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic protein required for neoplasia. CML is characterized by the t(9;22) that results in the bcr-abl fusion oncogene and in the expression of a chimeric protein product p210. Previously we have shown that peptides derived from amino acid sequences crossing the b3a2 fusion breakpoint in p210 elicit class I restricted… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 92 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 57 references

CD 4 1 cytotoxic T - cell clones specific for bcr - abl b 3 a 2 fusion protein augment colony formation by chronic myelogenous leukemia cells in a b 3 a 2specific and HLADRrestricted manner

  • W Chen, DJ Peace, DK Rovira, S You, MA Cheever
  • Blood
  • 1998

CD41 cytotoxic T-cell clones specific for bcr-abl b3a2 fusion protein augment colony formation by chronic myelogenous leukemia cells in a b3a2specific and HLA-DR-restricted

  • M Yasukawa, H Ohminami, S Kaneko
  • 1998

Similar Papers

Loading similar papers…